Advances in the treatment of neurodegenerative disorders employing nanoparticles

Recent Patents on Drug Delivery and Formulation

Volumn 6, Issue 1, 2012, Pages 2-18

  Spuch, Carlos ^a   Saida, Ortolano ^a   Navarro, Carmen ^a  

^a University Hospital of Vigo   (Spain)

Author keywords

Alzheimer's disease; Blood brain barrier; Brain; Central nervous system; Drug delivery; Nanoparticles; Nanotechnology; Neurodegenerative diseases; Parkinson's disease; Prion diseases; Therapeutics

Indexed keywords

ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE PLUS LEVODOPA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN M ANTIBODY; LEVODOPA; LEVODOPA PLUS TOLCAPONE; MEMANTINE; MONOCLONAL ANTIBODY; NANOPARTICLE; PHOSPHATIDYLGLYCEROL; PLASMID DNA; RIVASTIGMINE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN MONOCLONAL ANTIBODY; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CAPILLARY ELECTROPHORESIS; CONTROLLED DRUG RELEASE; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; MULTIINFARCT DEMENTIA; NANOBIOTECHNOLOGY; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR DEGENERATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 84857134413     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221112799219125     Document Type: Review

References (155)

1. OECD. Dementia Prevalence, in OECD, Health at a Glance: Europe 2010, OECD Publishing 2010; 54-55.
2. Forlenza O, Diniz B, Gattaz W. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Medicine 2010; 8:89.
3. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003; 4: 49-60.
4. Bertram L, Tanzi R. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115: 1449-57.
5. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112-7.
6. Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med 2011; 269: 54-63.
7. Pasic MD, Diamandis EP, McLaurin J, Holtzman DM, Schmitt-Ulms G, Quirion R. Alzheimer disease: Advances in pathogenesis, diagnosis and therapy. Clin Chem 2011; 57:5.
8. Morley JF, Hurtig HI. Current understanding and management of Parkinson disease: Five new things. Neurology 2010; 75: 9-15.
9. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90.
10. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991; 563: 311-4.
11. Lorenzo A, Yankner BA. Beta amyloid neurotoxicity requires fibril conformation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243-7.
12. Walker LC, Rosen RF, LeVine H. Diversity of Abeta deposits in the aged brain: A window on molecular heterogeneity? Rom J Morphol Embryol 2008; 49:5-11.
13. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001; 276: 12991-8.
14. Santos E, Zarate J, Orive G, Hernandez R, Pedraz J. Biomaterials in cell microencapsulation. Adv Exp Med Biol 2010; 670: 5-21.
15. Chang TM. Semipermeable microcapsules. Science 1964; 146: 524-5.
16. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glicolide) (PLGA) devices. Biomaterials 2000; 21: 2475-90.
17. Spuch C, Antequera D, Portero A, Orive G, Hernandez RM, Molina JA, et al. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioural impairment in a mouse model of Alzheimer's disease. Biomaterials 2010; 31: 5608-18
18. Spuch C, Navarro C. The therapeutic potential of microencapsulate implants: Patents and clinical trials. Rec Pat Endocrine, Metabolic & Immune Drug Discovery 2010; 4: 59-68.
19. Kincses ZT, Vecsej L. Pharmacological therapy in Parkinson disease: Focus on neuroprotection. CNS Neurosci Ther 2011; 17: 345-67.
20. Gustavsson A, Svensson M, Jacobi F, Allqulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; Sep 12. In press.
21. Henchcliffe C, Severt WL. Disease modification in Parkinson's disease. Drugs Aging 2011; 28: 605-15.
22. Osona-Nuñez L, Guisado-Macias JA, Pons M. Cognition and Lewy body disease. Actas Esp Psiquiatr 2011; 39: 267-70.
23. Ho GJ, Liang W, Waragai M, Sekiyama K, Masliah E, Hashimoto M. Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimer Dis 2011; 2011: 842475.
24. Jellinger KA, Attems J. Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders. Dement Geriatr Cogn Disord 2011; 31: 309-16.
25. Seeley WW, Zhou J, Kim EJ. Frontotemporal dementia: What can the behavioural variant teach us about human brain organization? Neuroscientist 2011; Jun 13, in press.
26. Gotz J, Eckert A, Matamales M, Ittner LM, Liu X. Modes of Abeta toxicity in Alzheimer's disease. Cell Mol Life Sci 2011; 20: 3359-75.
27. Rohrer JD. Structural brain imaging in frontotemporal dementia. Biocheim Biophys Acta 2011; Jul 30, in press.
28. Portugal Mda G, Marinho V, Laks J. Pharmacological treatment of frontotemporal lobar degeneration: systemic review. Rev Bras Psiquiatr 2011; 33: 81-90.
29. Enciu AM, Constantinescu SN, Popescu LM, Muresanu DF, Popescu BO. Neurobiology of vascular dementia. J Aging Res 2011; 2011: 401604.
30. Lasiene J, Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011; 2011: 718987.
31. nd edition, Boca Raton: CRC Press; 2011. Frontiers in Neuroscience ISBN: 978-0-8493-9000
32. Perlman SL. Spinocerebellar degenerations. Handb Clin Neurol 2011; 100: 113-140.
33. Teive HA. Spinocerebellar ataxias. Arq Neuropsiquitr 2009; 67: 1133-42.
34. Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz WK. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol 2011; 121:79-90.
35. Wadsworth JD, Collinge J. Molecular pathology of human prion disease. Acta Neuropathol 2011; 121: 69-77.
36. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Disc 2003; 2: 347-60.
37. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases: Alzheimer's disease and Parkinson's disease. J Drug Deliv 2011; in press.
38. Spuch C, Navarro C. Cell Microencapsulation Implants into the Central Nervous System. Rec Pat Nanomed 2011; 1: 60-7.
39. Spuch C, Navarro C. The therapeutic potential of cell encapsulation technology for drug delivery in neurological disorders. Edited by Rosario Pignatello. Published by Intech. Biomaterials science and engineering 2011; 20: 403-20. ISBN 978 953 307 609 6.
40. Dietrich M, Spuch C, Antequera D, Rodal I, De Yebenes JG, Molina JA, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008; 29: 902-12.
41. Spuch C, Navarro C. Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2). Rec Pat Endoc Metab Immun Drug Discov 2010; 4: 190-205.
42. Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood brain barrier and brain drug delivery. J Nanosci Naniotechnol 2006; 6: 2712-35.
43. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 1997; 145: 24-37.
44. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005; 2: 108-119.
45. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, et al. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res 2003; 20: 705-13.
46. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, et al. The controlled intravenous delivery of drugs using PEGcoated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995; 16: 215-33.
47. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80 coated poly(butyl cyanocrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44-8.
48. Senior J, Gregoriadis G. Is half life of circulating small unilamellar liposomes determined by changes in their permeability? FEBS lett 1982; 145: 109-114.
49. Kreuter J, Alyautdin R, Kharkevich D, Ivanov A. Passage of peptides through the blood brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171-4.
50. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug carrier. Int J Pharm 1983; 15: 335-45.
51. Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009; 10: 682-92.
52. Pardridge WM. Biophamarceutical drug targeting to the brain. J Drug Target 2010; 18: 157-67.
53. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011; 8: 7-9.
54. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, et al. PEGylated PLGA nanoparticles as preparation carriers: synthesis, preparation and biodistribution in rats. J Control Release 2001; 71: 203-211.
55. Blanco MD, Alonso MJ. Development and characterization of protein loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 1997; 43: 287-94.
56. Catena R, Santos E, Orive G, Hernandez RM, Pedraz JL, Calvo A. Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple repórter system. J Control Release 2010; 146: 93-8.
57. Chen W, Zhan C, Gu B, Meng Q, Wang H, Lu W, Hou H. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target 2011; 19: 228-234
58. Malavolta L., Cabral FR. Peptides: Important tools for the treatment of central nervous system disorders. Neuropeptides 2011; 45: 309-316.
59. Rae CS, Wei Khor I, Wang Q, Destito G, Gonzalez MJ, Singh P, et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 2005; 343: 224-35.
60. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006; 114: 1172-8.
61. Oberdorster G, Oberdorster E, Oberdorster J. Conceps of nanoparticle dose metric and response metric. Environ Health Perspect 2007; 117: 290.
62. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, et al. Biodistribution of 1.4 and 18 nm gold particles in rats. Small 2008; 4: 2108-11.
63. Beaton, A., Catchpoleian, R. Encapsulation of biologically active agents. TW2010006495 (2010).
64. Catchpoleian, R., Wayne, G.G., Papanicolau, I. Encapsulation of biologically active agents. WO2009135853 (2009).
65. Madhavan, N., Zainulabedin, S. Magnetic nanodelivery of therapeutic agents across the blood braion barrier. US2011213193 (2011).
66. Yehuda, I. Intracochlear drug delivery to the central nervous system. US2011213193 (2011).
67. McDonough, J., Dixon, H., Cabell, L. Nanoparticles for drug delivery to the central nervous system. US2011195125 (2011).
68. Krol, S., Lopez-Biota J. polyelectrolyte encapsulated gold nanoparticles capable of crossing blood brain barrier. US2011111040 (2011).
69. Sigalov, A. Methods and composition for targeted imaging. WO2011044545 (2011).
70. Wayne, G.G., Catchpoleian, R., Papanicolau, I., Beaton, A. Encapsulation of biologically active agents. MX2010012137 (2010).
71. Chuanhua, L., Lei, W. Preparation of brain targeting chuanxiogzine oral oil package oil nano-emulsion. CN101884614 (2010).
72. Chen, P., Yang, J., Zhuang, D. Drug delivering material taking vitamin C as hydrophilic fragments and preparation method thereof. CN101701061 (2010).
73. Hemant, S. Dendritic conjugates and methods of use. WO2009142754 (2009).
74. Jin, W.C., Jae-Hyun, L. Nanoparticles for penetration of blood brain barrier. WO2009136763 (2009).
75. Miqin, Z., Conroy, S., Omid, V., Narayan, B.I. Nanoparticles for brain tumor Imaging. US2010260686 (2010).
76. Ho, L.G., Ming, C.Y., Jeong, K.T., Young, P.J., Tae, W.S. Coated manganese oxide nanoparticles by biocompatible ligand and synthesizing thereof. KR20100078508 (2010).
77. Massoud, A., Jerome, E. Functionalized magnetic nanoparticles and methods of use thereof. KR20070121788 (2007).
78. Jayanth, P., Mahesh, C. Lipid derived nanoparticles for brain targeted drug delivery. WO2008024753 (2008).
79. Bright, C., Bright, R., Churchill, E., Leong, K.W., Mochly-Rosen, D. Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury. WO2008018932 (2008).
80. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G, Minn A. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J Neurochem1994; 62:1089-96.
81. Ghersi-Egea JF, Leininger-Muller B, Cecchelli R, Fenstermacher JD. Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett 1995; 82: 645-53.
82. Abbott NJ. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today: Technologies 2004; 1: 337-463.
83. Boer AB, Lange EL, Sandt ICJ, Breimer DD. Transporters and the blood-brain barrier (BBB) Int J Clin Pharmacol Ther 1998; 36:14-15.
84. Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323-55.
85. Pardridge WM. Molecular biology of the blood brain barrier. Mol Biotechnol 2005; 30: 57-70.
86. Pardridge WM. Molecular biology of the blood brain barrier. Methods Mol Med 2003; 89: 385-99
87. Golden PL, Pollack GM. Blood brain barrier efflux transport. J Pharm Sci 2003; 92: 1739-53.
88. Orive G, Hernández RM, Gascon AR, De Vos P, Hortelano G, Hunkeler D, et al. Cell encapsulation: Promise and progress. Nat Med 2003; 9: 104-7.
89. Orive, G., Hernandez, RM., Spuch, C., Antequera D, Carro E, Pedraz JL. Method for treating neurodegenerative diseases. WO2010089442 (2010).
90. Hernandez, R.M., Orive, G., Spuch, C., Antequera, D., Carro E, Pedraz JL, Use of microparticles containing genetically modifies cells in the treatment of neurodegenerative diseases. WO2010010223 (2010).
91. Aebischer P, Schluep M, Déglon N, Joseph JM, Hirt L, Heyd B, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2: 696-9.
92. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006; 103: 3896-901.
93. Spuch C, Antequera D, Portero A, Orive G, Hernandez RM, Molina JA, et al. The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioural impairment in a mouse model of Alzheimer's disease. Biomaterials 2010; 31: 5608-18.
94. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ. Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 1997; 145: 24-37.
95. Yamada K, Kinoshita A, Kohmura E, Sakaguchi T, Taguchi J, Kataoka K, et al. Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction. J Cereb Blood Flow Metab 1991; 11: 472-8.
96. Orive G, Ali OA, Anitua E, Peraz JL, Emerich DF. Biomaterialbased Technologies for brain anti-cancer therapeutics and imaging. Biochim Biophys Acta 2010; 1806: 96-107.
97. Bjerkvig, R. Alginate capsules for use in the treatment of brain tumour. US20056926888 (2005).
98. Allard E, Passirani C, Benoit JP. Convention enhanced delivery of nanocarriers for the treatment of brain tumours. Biomaterials 2009; 30: 2302-2318.
99. Rzigalinski, B., Ariane, C. Anti-inflammatory, radioprotective and longevity enhancing capabilities of cerium oxide nanoparticles. WO2007002662 (2007).
100. Rzigalinski, B., Cohen, C., Singh, N. Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease and disorders associated with free radical production and /or mitochondrial dysfunction. WO2009052295 (2009).
101. Rzigalinski, B., Singh, N., Cohen, C. Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease and disorders associated with free radical production and /or mitochondrial dysfunction. US2009092671 (2009).
102. Lautenschaeleger, H., Elias, I. New nanoparticles containing nicotine and/or cotinine useful e.g. for cigarette weaning and to treat e.g. attention-deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease and Binswanger'. DE102007017298 (2007).
103. Legname, G., Krol, S., Costa de Sousa, M. Gold nanoparticles coated with polyelectrolytes and use thereof as medicament for the treatment of neurodegenerative diseases caused by protein aggregates. WO2010052665 (2010).
104. Mook, I.H., Han, S.H., Chang, Y.J. Method for diagnosing Alzheimer's disease or dementia related neurological disease using gold nanoparticle. KR101003124 (2010).
105. Corot, C. Use of metal nanoparticles in the diagnosis of Alzheimer's disease. US2010111876 (2010).
106. Orive G, Hernandez RM, Gascon AR, Igartua M, Rojas A, Pedraz JL. Microencapsulation of an anti-VE-cadherin antibody secreting 1B5 hybridoma cells. Biotechnol Bioeng 2001; 76: 285-294.
107. Rodriguez, M., Miller, D.J., Pease, L.R. Human immunoglobulin M antibodies. US20097473423 (2009).
108. Singh N, Pillay V, Choonata YE. Advances in the treatment of Parkinson's disease. Prog Neurobiol 2007; 81: 29-44.
109. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008; 359: 2468-2476.
110. De Giglio, Trapani A, Cafagna D, Sabbatini L, Cometa S. Dopamine loaded chotosan nanoparticles: formulation and analytical characterization. Anal Bioanal Chem 2011; 400: 1997-2002.
111. Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monoesterate emusifiers: pharmacokinetic and behavioural evaluations. J Pharm Sci 2011; 100: 547-57.
112. Volvert AA, Subramaniam V, Ivanov MR, Goodman AM, Haes AJ. Salt-mediated self assembly of thioctic acid on gold nanoparticles. ACS Nano 2011; 5: 4570-80.
113. Ivanov MR, Haes AJ. Nanomaterial surface chemistry design for advancements in capillary electrophoresis modes. Analyst 2011; 136: 54-63.
114. Ziady AG, Gedeon CR, Miller T, Quan W, Payne JM, et al. Transfection of airway epithelium by stable PEGylated poly-L-Lysine DNA nanoparticles in vivo. Mol Ther 2003; 8: 936-47.
115. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body like pathology in long term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-6.
116. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient non viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006; 1:e38.
117. Yurek DM, Fletcher AM, Smith GM, Seroogy KB, Ziady AG, Molter J, et al. Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther 2009; 17; 641-50.
118. Yurek, DM, Fletcher AM., Kowalczyk TH, Padegimas L, Cooper MJ. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant 2009, 18: 1183-96.
119. Huang R, Ke W, Liu Y, Wu D, Feng L, Jiang C, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 2010; 290: 123-30.
120. Wu S, Ma C, Li G, Mai M, Wu Y. Intrathecal implantation of microencapsulated PC12 cells reduces cold allodynia in a model of neuropathic pain. Artif Organs 2011; 35: 294-300.
121. Roberts T, De Boni U, Sefton MV. Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer. Biomaterials 1996; 17: 267-75.
122. Ballard C, Kahn Z, Corbett A. Treatment of dementia with lewy bodies and parkinson's dementia. Drugs Aging 2011; 28: 769-77.
123. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71.
124. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, et al. Alpha synuclein suppression reverse synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011; 72: 57-71.
125. Fitzgerald P, Mandel A, Bolton AE, Sullivan AM, Nolan Y. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson's disease. Behav Brain Res 2008; 195: 271-4.
126. Milowska K, Malachowska M, Gabryelak T. PAMAM G4 dendrimers affect the aggregation of alpha-synuclein. Int J Biol Macromol 2011; 48: 742-6.
127. Knopman DS. Alzheimer's disease and other dementias. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier 2007: chapter 425.
128. Barmada SJ, Finkneiner S. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: Disease-associated pathways. Rev Neurosci 2010; 21: 251-72.
129. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010; 75: 2204-11.
130. Klein, R., Henning, P., Wang, D., Dayton, R., Tatom, J., Orchard, E. Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. US20110203007 (2011).
131. Enciu AM, Constantinescu SN, Popescu LM, Mures D, Popescu BO. Neurobiology of vascular dementia. J Aging Res 2011; 401604: 1-11
132. Cohen RA. Hypertension and cerebral blood flow: Implications for the development of vascular cognitive impairment in the elderly. Stroke 2007; 38: 1715-7.
133. Mogi M, Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circulation J 2011; 75: 1042-8.
134. Ritz MF, Fluri F, Engelter ST, Schaeren-Wiemers N, Lyrer PA. Cortical and putamen age related changes in the microvessel density and astrocytes deficiency in spontaneously hypertensive and stroke-prone spontaneously hypertensive rats. Current Neurovascular Research 2009; 6: 279-87.
135. Sung, H.W., Liang, H., Tu, H. Nanoparticles for protein drug delivery. US20117863257 (2011).
136. Li, Y., Gu, W., Chen, L. Huperzine, A and its derivates or salts sustained release nanometer granule and preparing method thereof. CN101264058 (2010).
137. Prusiner SB, Prions. Proc Natl Acad Sci 1998; 95: 13363-83
138. Dormont D. Prion diseases: pathogenesis and public health concerns. FEBS Let 2002; 592: 17-21.
139. Abid K, Soto C. Biomedicine and diseases: Review the intriguing prion disorders. Cell. Mol Life Sci 2006; 63: 2342-51.
140. Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, et al. Prion proteins: Physiological functions and role in neurological disorders. J Neurol Sci 2008; 264: 1-8
141. Tatzelt J, Schatzl HM. Molecular basis of cerebral neurodegeneration in prion disease. FEBS J 2007; 274: 606-11.
142. Wadsworth JDF, Collinge J. Update on human prion disease. Biochim Biophys Acta 1772; 598-609.
143. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci USA 1992; 89: 7620-4.
144. Aguzzi A, Glatzel M. Prion infections, blood and transfusions. Nat Clin Pract Neurol 2006; 2:321-9.
145. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med 2005; 11: 982-5.
146. Alvarez-Puebla RA, Agarwal A, Manna P, Khanal BP, Aldeanueva-Potel P, Carbó-Argibay E, et al. Gold nanorods 3Dsupercrystals as surface enhanced Raman scattering spectroscopy substrates for the rapid detection of scrambled prions. Proc Natl Acad Sci USA 2011; 108: 8157-61.
147. Xiao SJ, Hu PP, Wu XD, Chen LQ, Peng L, Ling J, et al. Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal Chem 2010; 82: 9736-42.
148. Zhang LY, Zheng HZ, Long YJ, Huang CZ, Hao JY, Zhou DB. CdTe quantum dots as a highly selective probe for prion protein detection: Colorimetric qualitative, semi-quantitative and quantitative detection. Talanta 2011; 83: 1716-20.
149. Miller MB, Supattapone S. Superparamagnetic nanoparticle capture of prions for amplification. J Virol 2011; 85: 2813-7.
150. Calvo P, Gouritin B, Brigger I, Lasmezas C, Desyls JP, Williams A, et al. PEGylated polycyanoacrylates nanoparticles as vector for drug delivery in prion diseases. J Neurosci Methods 2001; 111: 151-55.
151. Legname, G.A., Krol, S., Costa de Sousa, M.F. Gold nanoparticles coated with polyelectrolytes and albumin. US20112622546 (2011).
152. Cheon, J.W., Lee, J.H. Zinc containing magnetic nanoparticle based magnetic separation systems and magnetic sensors. WO2010151085 (2010).
153. Deasi, N., Peykov, V., Soon-Shiong, P. Prion free nanoparticle compositions and methods. WO2010121000 (2010).
154. Bergen JM, Park IK, Horner PJ, Pun SH. Nonviral approaches for neuronal delivery of nucleic acids. Pharm res 2008; 25: 983-98.
155. Legname, G.A., Krol, S., Costa de Sousa, M.F. Gold nanoparticles coated with polyelectrolytes and albumin. US2011262546 (2011)